Company profile for Evergreen Theragnostics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s unmatched expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commerc...
Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s unmatched expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs. Successful commercialization of theragnostic radiopharmaceuticals

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
95 Christopher Columbus Dr. 16th Floor Jersey City, NJ 07302
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader-302361401.html

PR NEWSWIRE
28 Jan 2025

https://www.businesswire.com/news/home/20241203929422/en

BUSINESSWIRE
03 Dec 2024

https://www.prnewswire.com/news-releases/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial-in-the-european-union-302280138.html

PR NEWSWIRE
18 Oct 2024

https://www.prnewswire.com/news-releases/evergreen-theragnostics-announces-licensing-of-evg321-from-medical-university-of-innsbruck-and-enters-clinical-development-of-radioligand-therapies-in-small-cell-lung-cancer-302151441.html

PR NEWSWIRE
21 May 2024

https://www.prnewswire.com/news-releases/evergreen-theragnostics-completes-26m-capital-raise-to-advance-novel-radiopharmaceutical-pipeline-into-the-clinic-prepare-for-first-commercial-product-launch-and-expand-industry-leading-cdmo-services-302115657.html

PR NEWSWIRE
16 Apr 2024

https://www.prnewswire.com/news-releases/uppi-and-evergreen-theragnostics-announce-partnership-for-sales-and-distribution-of-octevy-kit-for-preparation-of-ga-68-dotatoc-injection-pending-fda-approval-in-2h-2023-301936550.html

PR NEWSWIRE
25 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty